Kohno S
Department of Pharmacology, Kyoto Pharmaceutical University, Japan.
Nihon Yakurigaku Zasshi. 1998 Apr;111(4):223-31.
Peptide-leukotrienes (p-LTs) (LTC4, LTD4 and LTE4) are major metabolites of the arachidonate 5-lipoxygenase pathway. Although a number of papers have reported that p-LTs induce potent bronchial smooth muscle constriction as well as airway mucus secretion, vascular permeability and proliferation of airway smooth muscle cells, it had not been recognized that they are pivotal chemical mediators in asthmatic diseases until recently. Yet, several potent and selective antagonists against p-LTs and inhibitors of p-LT formation revealed that p-LTs play significant roles in not only allergic but non-allergic asthma including exercise- and aspirin-induced asthma. In addition, it has been reported that p-LTs participate in rhinitis, especially nasal blockage. In this article, recent development of drugs relating to p-LTs and their therapeutic effects for asthma are mainly reviewed.
肽白三烯（p-LTs）（LTC4、LTD4和LTE4）是花生四烯酸5-脂氧合酶途径的主要代谢产物。尽管许多论文报道p-LTs可诱导强效的支气管平滑肌收缩以及气道黏液分泌、血管通透性和气道平滑肌细胞增殖，但直到最近人们才认识到它们是哮喘疾病中的关键化学介质。然而，几种针对p-LTs的强效选择性拮抗剂以及p-LT形成的抑制剂表明，p-LTs不仅在过敏性哮喘中，而且在包括运动性和阿司匹林诱发的哮喘在内的非过敏性哮喘中都发挥着重要作用。此外，据报道p-LTs参与鼻炎，尤其是鼻塞。本文主要综述了与p-LTs相关的药物的最新进展及其对哮喘的治疗作用。
